Market Place
Sourcing Support
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
19 Nov 2024 //
GLOBENEWSWIRE
Abivax presents third quarter 2024 key financial information
14 Nov 2024 //
GLOBENEWSWIRE
Abivax Appoints Mark Stenhouse as Board Observer & Advisor
13 Nov 2024 //
GLOBENEWSWIRE
Abivax Congratulates Nobel Prize Winners For microRNA Discovery
07 Oct 2024 //
GLOBENEWSWIRE
Abivax: 25mg Obefazimod Shows 2-Year Success In Colitis Study
03 Oct 2024 //
GLOBENEWSWIRE
Abivax Enrolls 1st Patient In ENHANCE-CD Trial For Crohn`s Disease
03 Oct 2024 //
GLOBENEWSWIRE
Abivax To Present Obefazimod Abstracts At UEG Week 2024
26 Sep 2024 //
GLOBENEWSWIRE
Abivax Updates On UC Combination Therapy Program Strategy
25 Sep 2024 //
GLOBENEWSWIRE
Abivax presents first-half 2024 financial results
09 Sep 2024 //
GLOBENEWSWIRE
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
06 Aug 2024 //
GLOBENEWSWIRE
Abivax Provides Operational and Key Program Update
15 Jul 2024 //
GLOBENEWSWIRE
Abivax: Results Of May 30 General Meetings Released
04 Jun 2024 //
GLOBENEWSWIRE
Two biotechs go public while Apnimed bides its time
02 Oct 2023 //
FIERCE BIOTECH
Lexeo and Abivax seek Nasdaq listings in shrinking window for biotech IPOs
29 Sep 2023 //
ENDPTS
Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations
23 Aug 2023 //
ACCESSWIRE
Abivax Secures Up to EUR 150M from Two Structured Debt Financing Transactions
21 Aug 2023 //
ACCESSWIRE
Abivax Announces Plans to Conduct Registered Public Offering in United States
10 Aug 2023 //
ACCESSWIRE
Abivax Releases the Results of its June 5, 2023 Ordinary General Meeting
08 Jun 2023 //
ACCESSWIRE
Abivax Announces its Ordinary and Extraordinary General Meeting of June 5
15 May 2023 //
ACCESSWIRE
Publication of an expert article in JCC on obefazimod as promising therapeutic
02 May 2023 //
PHARMIWEB
Abivax Appoints Michael Ferguson as Chief Commerical Officer
18 Apr 2023 //
ACCESSWIRE
Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod
17 Apr 2023 //
ACCESSWIRE
Ex-CinCor CEO Marc de Garidel lands at Abivax after negotiating $1.8B cash sale
06 Apr 2023 //
ENDPTS
Abivax Adjusts its 2023 Financial Communication Calendar
16 Mar 2023 //
ACCESSWIRE
Abivax Publishes a Prospectus in the Context of its Capital Increase
23 Feb 2023 //
ACCESSWIRE
Abivax Announces Oversubscribed EUR 130M Cross-Over Financing at Market Price
22 Feb 2023 //
ACCESSWIRE
Abivax Appoints Dr. Sheldon Sloan, M.D., as Chief Medical Officer
17 Feb 2023 //
ACCESSWIRE
Abivax to Present Blood and Rectal Tissue Data from UC Patients
14 Feb 2023 //
ACCESSWIRE
Abivax Publishes Novel Data with Respect to Obefazimod’s Mechanism of Action
05 Jan 2023 //
ACCESSWIRE
Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod
20 Dec 2022 //
ACCESSWIRE
Abivax to Attend the J.P. Morgan 41st Annual Healthcare Conference
14 Dec 2022 //
ACCESSWIRE
Abivax Releases the Results of its November 9, 2022 Ad Hoc Meeting
15 Nov 2022 //
ACCESSWIRE
First US Patient Enrolled in Global Phase 3 Program with Obefazimod
11 Oct 2022 //
ACCESSWIRE
Abivax: first US patient enrolled in global ph3 program with obefazimod in UC
11 Oct 2022 //
PHARMIWEB
Abivax Presents First-Half 2022 Financial Results and Operations Update
15 Sep 2022 //
ACCESSWIRE
Abivax Phase 2b Study Results of Obefazimod (ABX464) in Ulcerative Colitis
05 Sep 2022 //
ACCESSWIRE
Facing €200M phase 3 bill, Abivax sells stock at knockdown price
03 Sep 2022 //
FIERCEBIOTECH
Abivax raises $49M to cross the PhIII finish line for ulcerative colitis drug
02 Sep 2022 //
ENDPTS
Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses
04 Aug 2022 //
ACCESSWIRE
Abivax Reports Efficacy and Safety Data of ABX464 Phase 2b Maintenance Trial
06 Apr 2022 //
ACCESSWIRE
Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results
10 Mar 2022 //
ACCESSWIRE
Abivax receive EMA scientific advice support for ulcerative colitis trial
12 Jan 2022 //
PHARMAFILE
Abivax Reports Long-Term Efficacy Data from Phase 2b Maintenance Trial of ABX464
20 Oct 2021 //
TRIALSITENEWS
ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax`s phase 2b
18 Oct 2021 //
PRESS RELEASE
Abivax Presents First-half 2021 Financial Results and Operations Update
23 Sep 2021 //
ACCESSWIRE
Abivax Provides an Update on the ABX464 Clinical Data
14 Sep 2021 //
ACESSWIRE
Abivax Announces Pricing of its Capital, Totaling EUR 85M New Financing
23 Jul 2021 //
BIOSPACE
Abivax’s ABX464 shows ‘impressive’ efficacy severe ulcerative colitis patients
25 May 2021 //
PHARMATIMES
Abivax completes induction treatment of last patient in ABX464 phase 2b
14 Apr 2021 //
PHARMIWEB
Abivax pulls the plug on its anti-inflammatory treatment; J&J says
09 Mar 2021 //
ENDPTS
DSMB recommends to halt Abivax’s phase 2b/3 miR-AGE Covid-19 clinical trial
07 Mar 2021 //
PHARMABIZ
Abivax Follows DSMB Recommendation to Stop the Phase 2b/3 miR-AGE
05 Mar 2021 //
YAHOO
qashes data of ABX464 induction and long-term maintenance phase 2a ulcerative
04 Mar 2021 //
BIOSPACE
Abivax Publishes Review in Drug Discovery Today on Mechanism of Action ABX464
05 Jan 2021 //
PRESS RELEASE
Abivax’s COVID-19 study declared Research National Priority by French government
23 Dec 2020 //
PMLIVE
Abivax’s COVID-19 study declared Research National Priority by French government
23 Dec 2020 //
PMLIVE
Abivax establishes clinical, regulatory and manufacturing framework for ABX464
09 Dec 2020 //
PRESS RELEASE
